Literature DB >> 17638887

Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor.

Conor C Lynch1, Tracy Vargo-Gogola, Michelle D Martin, Barbara Fingleton, Howard C Crawford, Lynn M Matrisian.   

Abstract

To delineate the role of matrix metalloproteinase 7 (MMP7) in mammary tumorigenesis, MMP7 was expressed in the normal murine mammary gland cell line, c57MG. MMP7 markedly enhanced the growth rate of the c57MG cells in three-dimensional culture and promoted tumor formation in vivo. Subsequent investigation showed that MMP7 (a) up-regulated ErbB4 receptor levels, (b) solubilized the ErbB4 receptor cognate ligand heparin-bound epidermal growth factor, and (c) mediated the proteolytic processing of ErbB4 to yield a soluble intracellular domain (ICD) that localized to the cytoplasm and the nucleus. Furthermore, overexpression of the ErbB4 ICD in the c57MG cell line recapitulated the proliferative effects of MMP7 in vitro and in vivo. These data indicate a novel mechanism for mammary epithelial cell transformation by MMP7.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638887     DOI: 10.1158/0008-5472.CAN-07-0026

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression.

Authors:  Steven T Sizemore; Ruth A Keri
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

Review 2.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

3.  Matrilysin (MMP-7) inhibition of BMP-7 induced renal tubular branching morphogenesis suggests a role in the pathogenesis of human renal dysplasia.

Authors:  John K McGuire; Susanna Harju-Baker; Cliff Rims; Joong-Hyuk Sheen; Helen Liapis
Journal:  J Histochem Cytochem       Date:  2012-01-03       Impact factor: 2.479

4.  Charge-Triggered Membrane Insertion of Matrix Metalloproteinase-7, Supporter of Innate Immunity and Tumors.

Authors:  Stephen H Prior; Yan G Fulcher; Rama K Koppisetti; Alexander Jurkevich; Steven R Van Doren
Journal:  Structure       Date:  2015-10-01       Impact factor: 5.006

5.  Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer.

Authors:  Iris Morath; Christian Jung; Romain Lévêque; Chen Linfeng; Robert-Alain Toillon; Arne Warth; Véronique Orian-Rousseau
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

Review 6.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

7.  Mammalian target of rapamycin (mTOR) induces proliferation and de-differentiation responses to three coordinate pathophysiologic stimuli (mechanical strain, hypoxia, and extracellular matrix remodeling) in rat bladder smooth muscle.

Authors:  Karen J Aitken; Cornelia Tolg; Trupti Panchal; Bruno Leslie; Jeffery Yu; Mohamed Elkelini; Nesrin Sabha; Derrick J Tse; Armando J Lorenzo; Magdy Hassouna; Darius J Bägli
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

8.  Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA.

Authors:  Conor C Lynch; Tracy Vargo-Gogola; Lynn M Matrisian; Barbara Fingleton
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

9.  Differential regulation of cell type-specific apoptosis by stromelysin-3: a potential mechanism via the cleavage of the laminin receptor during tail resorption in Xenopus laevis.

Authors:  Smita Mathew; Liezhen Fu; Maria Fiorentino; Hiroki Matsuda; Biswajit Das; Yun-Bo Shi
Journal:  J Biol Chem       Date:  2009-05-08       Impact factor: 5.157

10.  Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.

Authors:  Rajesh Subramaniam; Manas K Haldar; Shakila Tobwala; Bratati Ganguly; D K Srivastava; Sanku Mallik
Journal:  Bioorg Med Chem Lett       Date:  2008-04-16       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.